Fallen angels are few and far between, even at currently depressed stock market prices, but New York investor David Blech thinks he has found another one in Interferon Sciences Inc.

Blech, who is investing $10 million for a 26 percent stake in IFSC, told BioCentury, "The technology is really undervalued considering that they have some very strong data on the lack of toxicity of natural interferon to treat hepatitis